Acute coronary syndrome. Acute ischaemic heart disease, unspecified
Conditions
Interventions
Intervention 1: control: Clexan for 3 to 5 days at a dose of 60 mg subcutaneously injected. Intervention 2: Intervention: enoxaparin for 3-5 days at a dose of 60mg / bd subcutaneously injected.
Treatment - Drugs
control: Clexan for 3 to 5 days at a dose of 60 mg subcutaneously injected.
Intervention: enoxaparin for 3-5 days at a dose of 60mg / bd subcutaneously injected.
Sponsors
Shahroud University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: all patients with ACS (STEMI, NON STEMI, unstable angina) shahroud referring to Imam Hossein hospital. Exclusion criteria: the sensitivity of the lamina propria Anagza; those who have active bleeding; thrombocytopenia; previously received heparin.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major bleeding. Timepoint: Until discharge from hospital. Method of measurement: Observation.;Minor bleeding. Timepoint: Until discharge from hospital. Method of measurement: Sheet urinary analysis.;Thrombocytopenia. Timepoint: Until discharge from hospital. Method of measurement: Patient test page.;PTT. Timepoint: Until discharge from hospital. Method of measurement: Patient test page. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Reza Azarnia
Shahroud University of Medical Sciences and Health Services
Outcome results
None listed